文献速递青光眼

新型ab externo SIBS微引流管联合丝裂霉素C的中间结果

Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt With Mitomycin C.
PubMed 文献 · Am J Ophthalmol · 2020-03-13

该回顾性介入病例系列纳入164只开角型青光眼眼,接受ab externo SIBS微引流管联合丝裂霉素C(MMC)治疗,1年完全成功率为76.9%,条件成功率为92.5%。多变量分析显示MMC剂量0.2 vs 0.4-0.5 mg/mL及原发性 vs 继发性开角型青光眼是失败的危险因素。

要点

  • 1年完全成功率76.9%,条件成功率92.5%,眼压阈值14和21 mmHg下结果相近。
  • MMC 0.2 vs 0.4-0.5 mg/mL及POAG vs SOAG为失败独立危险因素(HR 2.51)。
  • 需针刺干预8.5%,手术翻修2眼,再手术1眼,并发症少。

核心结论

  • ab externo SIBS微引流管联合MMC在1年随访中显示较好的完全和条件成功率,降眼压药物使用减少,并发症少且术后干预不频繁。

主要发现

  • 1年完全成功率为76.9%,条件成功率为92.5%。
  • 眼压上限14 mmHg时完全成功率75.6%、条件成功率91.9%;21 mmHg时完全成功率76.9%、条件成功率92.5%。
  • 多变量分析中,MMC剂量0.2 vs 0.4-0.5 mg/mL(HR 2.51;95%CI 1.12-5.65)和原发性 vs 继发性开角型青光眼(HR 2.51;95%CI 1.01-6.23)是仅有的失败危险因素。
  • 8.5%的眼接受了针刺干预,2眼行手术翻修,1眼再手术。

关键数值与推荐

  • 完全成功:1年时无连续2次眼压>17 mmHg或临床低眼压,且不使用降眼压药物。
  • 条件成功:1年时无连续2次眼压>17 mmHg或临床低眼压,使用或不使用降眼压药物均可。
  • 附加标准:眼压较决策眼压降低至少20%。

临床怎么用

  • 对于开角型青光眼且无既往滤过手术史的患者,可考虑ab externo SIBS微引流管联合MMC作为降眼压手术选项。
  • 使用较高浓度MMC(0.4-0.5 mg/mL)可能降低失败风险,但需权衡。
  • 术后需监测眼压和并发症,必要时进行针刺或手术干预。

局限性

  • 回顾性研究设计。
  • 随访时间仅1年。
  • 单中心研究,样本来自特定人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the efficacy, risk factors for failure, and adverse events of a standalone novel ab externo SIBS microshunt with mitomycin C (MMC) during 1-year follow-up. DESIGN: Retrospective, interventional case series. SUBJECTS: Glaucomatous eyes with an intraocular pressure (IOP) above target and/or progressing on maximally tolerated medical therapy. METHODS: Consecutive patients with open-angle glaucoma (OAG) and no previous filtering surgery received an ab externo SIBS microshunt with MMC from July 2015 to November 2017. Main outcome measures were proportion of eyes at 1-year with (1) no 2 consecutive IOP readings >17 mm Hg or clinical hypotony without (complete) or with glaucoma medications (qualified); and (2) at least a 20% reduction from decision IOP. Secondary outcomes included upper IOP thresholds of 14 mm Hg and 21 mm Hg with and without a 20% IOP reduction from baseline, median IOP, medications, risk factors for failure, interventions, complications, and reoperations. RESULTS: A total of 164 eyes in 132 patients were included. Complete success was achieved in 76.9% of eyes, qualified success in 92.5%. Complete success was 75.6% for an upper IOP cut-off of 14 mm Hg and 76.9% for 21 mm Hg, and qualified success was 91.9% and 92.5%. MMC dose of 0.2 vs 0.4-0.5 mg/mL (hazard ratio [HR] 2.51; 95% CI 1.12-5.65) and primary open-angle glaucoma vs secondary open-angle glaucoma (SOAG) (HR 2.51; 95% CI 1.01-6.23) represented the only risk factors for failure in multivariable analysis. Needling was performed in 8.5% of eyes. Two eyes received surgical revision, and 1 a reoperation. CONCLUSIONS: One-year results of the ab externo SIBS microshunt demonstrated promising rates of qualified and complete success, decreased drop use, few complications, and infrequent postoperative interventions.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Schlenker MB, Durr GM, Michaelov E, et al. Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt With Mitomycin C. Am J Ophthalmol. 2020. PMID: 32173344. doi:10.1016/j.ajo.2020.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。